Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building strategies and community education programs.

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Nirsevimab, being developed in partnership with AstraZeneca, is the first investigational extended half-life monoclonal antibody (mAb) aiming to protect all infants entering their first RSV season ...

Nirsevimab, a monoclonal antibody recently approved to prevent respiratory syncytial virus-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season ...

Paris, May 11, 2022. Results from a prespecified pooled analysis of the pivotal Phase 3 MELODY and Phase 2b nirsevimab trials demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% ...